27.41 USD
↗ 0.00 (0.00%)AT CLOSE (11:59 AM EDT)
Roivant Sciences Ltd. Common Shares
ROIVNASDAQ • USD
27.13
↘ 0.28 (1.02%)
POST MARKET (AS OF 07:10 PM EDT)
Post Market
AS OF 07:10 PM EDT
27.13
↘ 0.28 (1.02%)
Market: CLOSED
Open?$28.24
High?$28.32
Low?$27.06
Prev. Close?$27.41
Volume?5.6M
Avg. Volume?5.3M
VWAP?$27.59
Rel. Volume?1.05x
Bid / Ask
Bid?$26.86 × 300
Ask?$27.40 × 100
Spread?$0.54
Midpoint?$27.13
Valuation & Ratios
Market Cap?19.6B
Shares Out?715.7M
Float?371.0M
Float %?51.8%
P/E Ratio?N/A
P/B Ratio?4.60
EPS?-$1.13
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?30.66Strong
Quick Ratio?30.66Strong
Cash Ratio?9.73Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUED
Score58/100
P/E?N/A▾
P/B?4.60FAIR▾
P/S?1,473.88HIGH▾
P/FCF?N/A▾
EV/EBITDA?-15.0CHEAP▾
EV/Sales?1,362.82HIGH▾
Returns & Efficiency
ROE?-19.0%WEAK▾
ROA?-15.5%WEAK▾
Cash Flow & Enterprise
FCF?$-766855000
Enterprise Value?$18.1B
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Employees
750
Market Cap
19.6B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2021-10-01
Address
7TH FLOOR, 50 BROADWAY
LONDON, SW1H 0DB
Phone: 441-295-5950
LONDON, SW1H 0DB
Phone: 441-295-5950